CVS Health Corp vs Valero Energy Corporation — how do they compare? CVS Health Corp trades at $87.04 (market cap $112.29B), while Valero Energy Corporation trades at $441.87 (market cap $127.78B). The key difference: CVS Health Corp and Valero Energy Corporation are close in size by market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Valero Energy Corporation for 56 Days on average.
| CVS | VLO | |
|---|---|---|
Market Cap | $112.29B | $127.78B |
Volume | 7,763,676 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $110.60 | $443.80 |
52-Week Low | $70.08 | $156.39 |
Typical Hold Time | 83 Days | 56 Days |
Enterprise Value | $174.64B | $131.26B |
Dividend Yield | 3.03% | 1.08% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.12, down 0.94% on the day, with strong analyst support showing 85% buy ratings and a $111.20 consensus price target. The stock demonstrates solid revenue growth, reaching $402.07 billion in 2025, though net margins compressed to 1.18%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 forecast. Technical indicators show a bearish trend with key support at $85.
CVS presents a compelling value opportunity with attractive valuation ratios (P/E 23.17, P/S 0.27) and consistent dividend payments. However, declining profit margins and ongoing regulatory scrutiny pose risks. The company's Medicare expansion and healthcare services growth provide upside potential, but investors should monitor reimbursement pressures and competitive dynamics in the evolving healthcare landscape.
Valero Energy (VLO) trades at $441.93, up 4.2% today, near its 52-week high with strong bullish momentum from moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 expected at $20.17 EPS. Revenue declined to $122.69B in 2025, but net income margin improved to 5.17%, supported by a robust ROE of 29.31%. Analyst consensus is bullish with a $408.10 price target, though RSI levels indicate overbought conditions.
VLO's outlook is positive due to refining margin strength and earnings beats, but risks include volatile energy prices and potential policy impacts like diesel export bans. The stock offers growth potential with a reasonable P/E of 18.51, yet high valuation multiples and technical overbought signals warrant caution for near-term entries.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →